Therma Bright's AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Detects the Important SARS-CoV-2 Variants of Concern; the Brazilian P.1 and P.2 and the UK B.1.1.7 Variants

Stock Information for Therma Bright Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Therma Bright Inc.

Therma Bright Announces Strategic Review & Update on Investment in Inretio
Canadian Investment Regulatory Organization Trade Resumption - THRM
Therma Bright's Venowave Accepted for Review By Center for Medicare & Medicaid Services for Permanent CPT and HCPCS codes
Therma Bright Provides Update on Cease Trade Order
Canadian Investment Regulatory Organization Trading Halt - THRM
Therma Bright Prepares FDA 513(g) Review Document for its AI-Driven Digital Cough Analyzer (DCA)
Therma Bright Announces Venowave Pilot Tests with Existing and New Distribution Partners in the United States
TSX Venture Exchange Stock Maintenance Bulletins

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.